Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 19/20 | 0.61 |
| ▸ | NPY1R | P25929 | 12/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.61 |
| ▸ | NPY2R | P49146 | 8/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31114992 | 0.96 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30471341 | 0.93 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31114995 | 0.91 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31114991 | 0.90 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31114984 | 0.88 | NPY4R (0.78) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31114993 | 0.87 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30471344 | 0.84 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL25627280 | 0.83 | REN (0.61) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30471380 | 0.83 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30471264 | 0.82 | NPY4R (0.69) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4700039-A1 | PEPTIDE, AND COMPOSITION THEREOF AND USE THEREOF | Winkey Technology USA Inc (US) | 2026-02-25 | — | — | EP | claimed |
| WO-2024217505-A1 | PEPTIDE, AND COMPOSITION THEREOF AND USE THEREOF | 深圳市维琪科技股份有限公司 | 2024-10-24 | — | — | WO | claimed |
| CN-117327150-B | Peptides, compositions and uses thereof | 深圳市维琪科技股份有限公司 | 2024-09-27 | — | — | CN | claimed |
| EP-4700039-A1 | PEPTIDE, AND COMPOSITION THEREOF AND USE THEREOF | Winkey Technology USA Inc (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20260049103-A1 | PEPTIDE, AND COMPOSITION THEREOF AND USE THEREOF | WINKEY TECH USA INC (US) | 2026-02-19 | — | — | US | disclosed |
| WO-2024217505-A1 | PEPTIDE, AND COMPOSITION THEREOF AND USE THEREOF | 深圳市维琪科技股份有限公司 | 2024-10-24 | — | — | WO | disclosed |
| CN-117327150-B | Peptides, compositions and uses thereof | 深圳市维琪科技股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049103-A1 | PEPTIDE, AND COMPOSITION THEREOF AND USE THEREOF | ARG1, ARGLU1, ARG2 | NPY4R 14/4885NPY1R 5/4885NPY5R 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.